Atty Dkt No. PP00154.206

USSN: 09/929,782

PATENT

I. AMENDMENT

In the Claims:

The following listing reflects amendments to the claims and replaces all prior

versions and listings of claims in this application.

1-19. (Cancelled)

20. (Currently amended) An assay kit for detecting the presence of a hepatitis C

virus (HCV) glycoprotein having mannose-terminated glycosylation, wherein less than about

10% of the total N-linked carbohydrate on said HCV glycoprotein is sialic acid, wherein said

HCV glycoprotein is selected from the group consisting of a glycoprotein expressed from the

E1 region of HCV, a glycoprotein expressed from the E2 region of HCV, and aggregates

thereof, said kit comprising:

a solid support;

a mannose-binding protein that binds a protein having mannose terminated

glycosylation; and

an isolated antibody reactive with said HCV glycoprotein;

wherein one of said antibody and said mannose binding protein is bound to said solid

support.

21. (Original) The assay kit of claim 20, wherein said mannose-binding

protein is GNA.

22. (Original) The assay kit of claim 20, wherein said antibody is bound

to said support and said mannose-binding protein is bound to a detectable label.

23. (Original) The assay kit of claim 20, wherein said mannose-binding

protein is bound to said support and said antibody is bound to a detectable label.

-2-

Atty Dkt No. PP00154.206

USSN: 09/929,782

PATENT

24-68. (Cancelled)

69. (Previously presented) The assay kit of claim 20, wherein said HCV

glycoprotein is a glycoprotein expressed from the E1 region of HCV.

70. (Previously presented) The assay kit of claim 20, wherein said HCV

glycoprotein is a glycoprotein expressed from the E2 region of HCV.

71. (Previously presented) The assay kit of claim 20, wherein said HCV

glycoprotein is an aggregate of a glycoprotein expressed from the E1 region of

HCV and a glycoprotein expressed from the E2 region of HCV.

72. (Previously presented) The assay kit of claim 20, wherein said HCV

glycoprotein is an aggregate of glycoproteins expressed from the E1 region of

HCV.

73. (Previously presented) The assay kit of claim 20, wherein said HCV

glycoprotein is an aggregate of glycoproteins expressed from the E2 region of

HCV.

74. (Previously presented) The assay kit of claim 20, wherein the antibody

is a polyclonal antibody.

75. (Previously presented) The assay kit of claim 69, wherein the antibody

is a polyclonal antibody.

76. (Previously presented) The assay kit of claim 70, wherein the antibody

is a polyclonal antibody.

-3-

Atty Dkt No. PP00154.206 USSN: 09/929,782

PATENT

77. (Previously presented) The assay kit of claim 71, wherein the antibody is a polyclonal antibody.

- 78. (Previously presented) The assay kit of claim 72, wherein the antibody is a polyclonal antibody.
- 79. (Previously presented) The assay kit of claim 73, wherein the antibody is a polyclonal antibody.